comprehensive -WSS

comprehensive

author：entertainment 2025-10-01 21:35:36 - browse：1824

From left: Daphne Koller, CEO of Insitro, Vijay Pande of Andreessen Horowitz and scientist Derek Lowe speaking at STAT's Breakthrough Summit in San Francisco. Sarah Gonzalez for STAT

Artificial intelligence is a rapidly improving technology. But its progress in drug development faces an increasingly urgent threat: An unending stream of overheated marketing.

To read of AI’s feats in press releases is to learn of a miracle product on the verge of unraveling biology’s most enduring secrets. It can map molecules and accurately predict how they fit together on computer screens. All you need to get to a cure — as they say in infomercials — is act now!

“I am very worried about the hype,” said Daphne Koller, chief executive of the machine learning drug discovery company Insitro, said during STAT’s Breakthrough West Summit in San Francisco last week. “People think (the breakthrough) is going to happen tomorrow.”

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The high cost of giving birth even with insurance
Next article： U.K. considers world's first use of meningitis vaccine to address gonorrhea

hotspot

WSS

Hospitals look to new technology to keep health care workers safe

Elisabeth Bik tackles the widespread issue of research misconduct

Readout Newsletter: The latest on Amylyx, Moderna, Novavax

Readout LOUD podcast: A CRISPR milestone, biotech mixology

A daunting task: navigating dual Medicare, Medicaid eligibility

Pfizer is about to make a big push in cancer. Will investors listen?

focus

comprehensive

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

Wikipedia

How one medical school became remarkably diverse

Childhood cancer progress stalls for Black, Hispanic kids: Report

Cancer drug shortages should be causing more outrage

Are embryos people? Reproductive medicine's future depends on the answer

In Memoriam: Notable people who died in 2023

NEJM study measures Covid brain fog, impact on IQ

23andMe had bad news about my health. I wish a person had delivered it

Change Healthcare cyberattack shows risk of industry consolidation

Psychedelics group wrestles with new pharma identity

Doctor of U.S. President Joe Biden says he is fit for duty

leisure time

Cholera vaccine supplies dangerously low, outbreaks surging

PBM reforms clear House panel

A daunting task: navigating dual Medicare, Medicaid eligibility

Ransomware attacks on hospitals: Study outlines patient impact

Are embryos people? Reproductive medicine's future depends on the answer

Using force crossed my mind when examining a defiant young patient

hotspot

hotspot

focus

Wikipedia